Renexxion - Ireland
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Regulatory Developments
  • Knowledge Centre
    • Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
    • Gastroparesis
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • PPI non-responsive GERD
  • News
    • Press >
      • ​Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Completion of Enrollment of the Global Phase 2b Study Evaluating Naronapride in Gastroparesis (MOVE-IT)
      • Renexxion Ireland Ltd. Announces Issuance of Fifth New U.S. Patent Covering Novel Crystal Isoform of Naronapride
      • Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient
      • Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States
      • Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
      • Renexxion to Present at the Oppenheimer 34ᵗʰ Annual Healthcare Life Sciences Conference
      • Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD
      • Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD
      • Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride
      • ​Renexxion to Present at the Oppenheimer Healthcare Private Company Showcase​
      • Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
      • Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
      • Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
      • Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
      • Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
  • Contact
Download .pdf

Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment 

ROSCREA, Ireland, 12th April, 2022 /PRNewswire/ – Renexxion Ireland Ltd., a private 
biopharmaceutical company committed to delivering innovative drugs to patients with high unmet need 
in gastrointestinal (“GI”) disorders, announced today that it has entered into a share subscription 
agreement with GEM Global Yield LLC SCS (“GEM”), a Luxembourg-based private equity group for an 
investment of up to $100 Million to be made within 36 months after a public listing. In this tailored 
agreement, Renexxion Ireland will control the amount and timing of any drawdowns under this facility 
with no minimum subscription obligation and will issue shares of common stock. The proceeds from 
this capital investment will further the company’s lead program, naronapride and advance additional 
new programs. 

“The benefits of a funding commitment from a strong institutional investor like GEM are certainty and 
faster access to capital as a publicly listed company, critical elements for rapid growth,” said Peter 
Milner M.D., FACC, Chairman and CEO. 

Renexxion Ireland’s lead program is naronapride, a late-stage potential best-in-class drug candidate for 
unmet GI indications in the upper and lower GI tract. In scientific studies naronapride has been 
demonstrated to possess a unique combination of both serotonin 5HT4 receptor agonistic and 
dopamine D2 receptor antagonistic properties, both clinically validated targets. Naronapride is designed 
to be minimally absorbable, is locally active in gut lumen, and in clinical studies its side-effect profile is 
indistinguishable from placebo. Four positive Phase-II studies have been completed and naronapride is 
Phase-III ready in chronic idiopathic constipation (CIC) and gastro-esophageal reflux disease (GERD). 
Renexxion Ireland is currently advancing an additional research program in inflammatory bowel disease 
(“IBD”). 


About Renexxion: 
Renexxion Ireland Ltd. is an Irish privately held biopharmaceutical company committed to delivering 
new drugs to patients with GI disorders. Renexxion Ireland is currently collaborating with a leading 
European GI Licensing partner to advance naronapride through the later stages of development and 
commercialization in Greater Europe and certain other Australasian countries.  (For information:   
https://www.prnewswire.com/news-releases/renexxion-ireland-ltd-announces-a-licensing-and-
collaboration-agreement-with-dr-falk-pharma-gmbh-301392102.html
 ).

For information: http://www.rnexltd.ie 


About the GEM Group 
GEM Global Yield LLC SCS, part of the Global Emerging Markets Group, is a $3.4 billion, alternative 
investment group with offices in Paris, New York, and Nassau (Bahamas). GEM manages a diverse set of 
investment vehicles and has completed over 500 transactions in 70 countries. For information: 
http://www.gemny.com 


Contact:
​Catherine Pearson, Chief Operating Officer, at [email protected], or on +353 61 539121. 
Privacy Policy & Terms of Use
Copyright RENEXXION IRELAND LTD  2025  All rights reserved.
  • Home
  • Company
    • Our Vision
    • Our Leadership Team
  • ​Naronapride (ATI-7505)
    • About Naronapride (ATI-7505)
    • Mechanism of Action
    • Development Status
    • Chemistry and Manufacturing
    • Regulatory Developments
  • Knowledge Centre
    • Gastrointestinal Dysmotility in Cystic Fibrosis (CF)
    • Gastroparesis
    • Chronic Idiopathic Constipation
    • Irritable Bowel Syndrome
    • PPI non-responsive GERD
  • News
    • Press >
      • ​Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Completion of Enrollment of the Global Phase 2b Study Evaluating Naronapride in Gastroparesis (MOVE-IT)
      • Renexxion Ireland Ltd. Announces Issuance of Fifth New U.S. Patent Covering Novel Crystal Isoform of Naronapride
      • Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Expansion of the Phase 2b MOVE-IT Study of Naronapride in Gastroparesis and Dosing of the First United States Patient
      • Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce FDA Clearance of the Investigational New Drug Application for Naronapride to Treat Gastroparesis and Subsequent Expansion of the Ongoing Phase 2b MOVE-IT Study to the United States
      • Renexxion Ireland’s European Partner, Dr. Falk Pharma GmbH, has Elected PPI-non-responsive Symptomatic GERD as the Second Naronapride Indication to Develop and Commercialize in their Licensed Territories
      • Renexxion to Present at the Oppenheimer 34ᵗʰ Annual Healthcare Life Sciences Conference
      • Renexxion Ireland Ltd. Announces FDA Clearance of Investigational New Drug (IND) Application for Naronapride to Treat PPI-Non-Responsive Symptomatic GERD
      • Renexxion Ireland has Completed a Successful Pre-IND Consultation with the United States FDA for Development of Naronapride for Patients with PPI-non-responsive Symptomatic GERD
      • Renexxion Ireland Announces Issuance of Two U.S. Patents Covering a Novel Crystal Isoform of Naronapride
      • ​Renexxion to Present at the Oppenheimer Healthcare Private Company Showcase​
      • Renexxion Ireland Ltd. and Dr. Falk Pharma GmbH Announce Initiation of Phase II Study of naronapride in patients with gastroparesis
      • Renexxion Announces Opening of Investigational New Drug (IND) Application for Naronapride for the Treatment of Gastrointestinal Dysmotility in Cystic Fibrosis Patients
      • Gastrointestinal Biotech Company Renexxion Ireland Announces $100M Investment Commitment
      • Renexxion Ireland Announces Issuance of a New US Patent covering Naronapride, a Clinical Stage Potential Best-in-Class Prokinetic Agent for Gastrointestinal Disorders
      • Renexxion Ireland Ltd. Announces a Licensing and Collaboration Agreement with Dr. Falk Pharma GmbH
  • Contact